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1. Need for novel treatment options in 
hepatocellular carcinoma (HCC) 
HCC is still one of the leading causes of death caused by cancer 
worldwide [1]. Despite different curative treatment modalities 
available, advanced-stage HCC has a poor prog- nosis and high 
tumor recurrence rate. Since  early  stages  of HCC are 
asymptomatic, many patients represent with non- resectable 
advanced-stage tumors. In every respect, early diagnosis of HCC 
is the key for a  survival  benefit  because only in early stages 
treatment options such as resection, liver transplantation, or 
nonsurgical approaches are available and lead to improved 
outcomes [2]. 
The pan-tyrosine kinase inhibitor sorafenib is the only stan- 
dard drug therapy available for patients with  advanced  HCC, with 
modest effectiveness at extending the overall survival of patients 
for 2–3 months. The mechanism  by  which  sorafenib acts on 
advanced HCC is not well understood, and no biomar- kers have 
been identified to predict response to sorafenib treatment in 
patients with HCC [3]. Moreover, resistance to sorafenib and 
severe side effects further limit its clinical efficacy [3]. One factor 
which could play a role in the resistance to sorafenib is sirtuin 1 
(SIRT1). Sirtuins are a family of nicotina- mide adenine 
dinucleotide (NAD)-dependent enzymes that modulate distinct 
metabolic, energetic, and stress response pathways. In a recent 
study, higher SIRT1  protein  levels  in HCC tissue were 
associated with worse outcome, and SIRT1 overexpression 
supported resistance to sorafenib [4]. SIRT1 activity depends on 
intracellular NAD levels. Nicotinamide phos- 
phoribosyltransferase (NAMPT) is the key enzyme in mamma- 
lian NAD salvage from nicotinamide and therefore regulates the 
activity of NAD-dependent enzymes, such as sirtuins or poly- 
ADP-ribosyltransferases (PARPs) (reviewed in [5], Figure 1). 
 
2. Inhibition of NAD biosynthesis in HCC 
Cancer cells have a higher demand for NAD because of their 
rapid proliferation which is associated with the need for 
increased energy metabolism, ATP generation, nucleotide 
biosynthesis,   DNA   repair,   and   increased   activity   of   NAD- 
consuming enzymes [6]. NAMPT has been extensively  stu- died 
as a target of anticancer therapy. NAMPT is overex- pressed in 
several types of tumor tissue and  its  expression often correlates 
with cancer therapy resistance and poor outcome in cancer 
patients [6]. NAMPT inhibitors as single agents have not been 
applied successfully in clinical studies so far [6]. Possible 
successful treatment combinations with NAMPT inhibitors 
include DNA-damaging agents, inhibitors targeting enzymes 
involved in cellular stress responses  or DNA repair, and rescue 
with nicotinic acid in nicotinic acid phosphoribosyltransferase-
negative tumors to increase tol- erance of non-tumor tissue to 
NAMPT inhibition [6]. Another promising  possibility  is  the  
simultaneous  inhibition   of NAMPT and other enzymes 
providing precursors for NAD biosynthesis, e.g. cluster of 
differentiation 73 [7]. 
We found that NAMPT expression is lower in hepatocarci- 
noma cell lines compared to primary hepatocytes. NAMPT 
enzymatic activity, however, is higher in HCC with the result 
of comparable NAD levels in HCC cell lines and primary hepa- 
tocytes [8]. Nevertheless, blocking NAMPT enzymatic activity by 
the specific inhibitor FK866 induced depletion of NAD and ATP 
and delayed cell death in human hepatocarcinoma cell lines. 
FK866 treatment induced adenosine monophosphate-activated 
kinase (AMPK) activation while the activity of mammalian target 
of rapamycin (mTOR) complex 1 and downstream targets was 
blocked [9]. We and others showed that the catalytic subunit of 
AMPK is significantly downregulated while mTOR complex 
1 activation is higher in HCC compared to primary hepatocytes 
or normal liver tissue [9,10]. Thus, increasing AMPK activity 
by inducing energy stress through NAMPT inhibition or by 
Metformin, an activator of AMPK, could help to antagonize 
the Warburg effect and could become a novel option for the 
treatment of HCC [11]. 
The polyphenol resveratrol was found to inhibit carcino- 
genesis in different types of cancer with a pleiotropic mode of 
action and has been considered in HCC prevention and treat- 
ment [12]. We found that resveratrol treatment of hepatocar- 
cinoma cell lines led to cell cycle arrest and apoptosis with 
concomitant reduced NAMPT activity and NAD levels, which 
resulted in reduced SIRT1 activity [8]. 
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Figure 1. Potential mechanism of NAMPT-NAD-SIRT1 action in HCC. 
Nicotinamide phosphoribosyltransferase (NAMPT) catalyses the salvage of nicotinamide (NAM), a reaction product of Sirtuin (SIRT) 1, to 
nicotinamide mononucleo- tide (NMN). FK866 is a specific pharmacologic inhibitor of NAMPT enzymatic activity, which leads to depletion of 
intracellular nicotinamide adenine dinucleotide (NAD) levels. Conversion of NMN to NAD is carried out by nicotinamide mononucleotide 
adenylyltransferase (NMNAT) enzymes. NAD is a substrate for SIRT1. By deacetylating specific lysine residues, SIRT1 regulates the transcriptional 
activity or protein stability of several crucial factors in hepatocarcinoma (HCC) tumorigen- esis. YAP: Yes-associated protein; c-MYC: V-Myc Avian 
Myelocytomatosis Viral Oncogene Homolog; TERT: telomerase catalytic subunit; p53: tumor suppressor protein 53; PTEN: phosphatase and tensin 
homolog; Data from Wu et al. Tumor Biol. (2015) 36:4063–4074. 
 
 
3. Extracellular NAMPT in HCC 
In addition to its key role in intracellular NAD biosynthesis, 
NAMPT (also known as visfatin or pre-B cell colony-enhancing 
factor in this context) is also found in human circulation. 
Extracellular NAMPT was found to  act both as  enzyme, con- 
verting nicotinamide to nicotinamide mononucleotide (NMN), 
and as cytokine (reviewed in [5]). Increased NAMPT serum 
concentrations have been associated with a variety of cancers 
and extracellular NAMPT was found to influence the microen- 
vironment of cancer cells in a way to promote tumor progres- 
sion and metastasis [13]. In patients with HCC, serum NAMPT 
levels were significantly correlated with stage progression and 
tumor enlargement. Extracellular NAMPT preferentially stimu- 
lated the proliferation of human HCC cell lines compared with 
normal hepatocytes via activation of extracellular signal-regu- 
lated kinase and V-Akt Murine Thymoma Viral Oncogene 
Homolog 1 pathways and glycogen synthase kinase-3β [14]. 
Similar results for extracellular NAMPT action have been found 
in breast cancer [15]. 
 
 
4. Boosting NAD levels in HCC 
One of the cellular events preceding HCC development is 
oncogene-induced DNA damage. Expression of unconven- 
tional prefoldin RBP5 interactor in hepatocytes was shown 
to reduce the expression of enzymes of de novo NAD bio- 
synthesis. The resulting NAD depletion induced DNA 
damage by inhibiting the NAD-dependent DNA repair 
enzyme PARP-1, subsequent genotoxic stress, apoptosis, and 
compensatory proliferation leading to the development of 
liver tumors in mice [16]. HCC development was blocked by 
the restoration of hepatocellular NAD pools by supple- 
menting nicotinamide ribose, a precursor of NAD biosynth- 
esis [16]. HCC is also driven by hepatocyte death during 
progression of non-alcoholic fatty liver disease (NAFLD). 
Studies on NASH patients and animal models revealed that 
there is a negative correlation  of NAMPT expression and 
NAFLD progression. We could demonstrate that during 
early stage NAFLD, NAD salvage via NAMPT is 
upregulated in mice [17], whereas in later disease stages, 
NAMPT and NAD levels were reported to be downregulated 
(reviewed in [5]). Low NAD levels may then reduce the 
activity of PARP-1, thereby impairing genomic integrity as 
was described by Tummala et al. [16]. 
5. Conclusion 
HCC is an extremely heterogeneous cancer, varying 
widely in etiology (genotoxic stress, metabolic disorders) 
and pro- gression in individual patients [2]. Both NAD 
depletion (e.g. via NAMPT inhibition) and NAD 
replenishment could be beneficial in the prevention and 
treatment of HCC, espe- cially in case of sorafenib 
resistance. Boosting NAD levels could be a preventive 
treatment, especially since recent studies on long-term  
supplementation  of  NAD  precursors or intermediates did 
not show obvious toxicity or deleter- ious effects and 
increased NAD levels in mouse liver [18,19]. Early 
therapeutic intervention prior to genomic instability may 
protect risk patients from tumor initiation and geno- 
toxic-induced tumorigenesis. 
Future studies focusing on inhibition of NAD 
biosynthesis in hepatocarcinoma animal models could help 
to elucidate questions regarding the timing of NAD 
inhibition (early vs. advanced stage tumors), finding 
biomarkers to predict response to NAMPT inhibitor 
treatment and test drug combi- nations that enhance the 
efficiency of NAD depletion. Complete inhibition of 
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NAMPT is crucial to prevent tumor recurrence, as 
incomplete NAMPT inhibition, which impedes NAD+ 
metabolism but does not kill a tumor cell, can alter its 
phenotype to be more aggressive and metastatic [20]. 
Unraveling the role of NAMPT activity in HCC 
development and the function of NAMPT’s non-enzymatic 
activity in inflam- mation, angiogenesis and metastasis will 
pave the way for future novel NAMPT-based oncotherapy 
options for HCC. 
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